POSACONAZOLE - Generic Drug Details

What are the generic drug sources for posaconazole and what is the scope of freedom to operate?

Posaconazole is the generic ingredient in three branded drugs marketed by Msd Merck Co, Merck Sharp Dohme, Aspiro, Eugia Pharma, Fresenius Kabi Usa, Gland, Mylan Labs Ltd, Ph Health, Schering, Hikma, Actavis Labs Fl Inc, Aet Pharma, Amneal, Aurobindo Pharma, Biocon Pharma, Dr Reddys, Hetero Labs Ltd Iii, I 3 Pharms, MSN, Qilu Pharm Hainan, Sinotherapeutics Inc, Specgx Llc, and Welding, and is included in twenty-four NDAs. There are six patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Posaconazole has eighty-one patent family members in twenty-four countries.

There are twenty-one drug master file entries for posaconazole. Twenty-nine suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for POSACONAZOLE

International Patents:	81
US Patents:	6
Tradenames:	3
Applicants:	23
NDAs:	24
Drug Master File Entries:	21
Finished Product Suppliers / Packagers:	29
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	94
Patent Applications:	3,054
Drug Prices:	Drug price trends for POSACONAZOLE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for POSACONAZOLE
What excipients (inactive ingredients) are in POSACONAZOLE?	POSACONAZOLE excipients list
DailyMed Link:	POSACONAZOLE at DailyMed

See drug prices for POSACONAZOLE

Recent Clinical Trials for POSACONAZOLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Minnesota	PHASE3
AstraZeneca	PHASE1
Tongji Hospital	NA

See all POSACONAZOLE clinical trials

Generic filers with tentative approvals for POSACONAZOLE

Applicant	Application No.	Strength	Dosage Form
		18MG	INJECTION;SOLUTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for POSACONAZOLE

Drug Class

Azole Antifungal

Anatomical Therapeutic Chemical (ATC) Classes for POSACONAZOLE

J02AC	Triazole and tetrazole derivatives
J02A	ANTIMYCOTICS FOR SYSTEMIC USE
J02	ANTIMYCOTICS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for POSACONAZOLE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NOXAFIL	Injection	posaconazole	18 mg/mL, 16.7 mL vials	205596	1	2015-11-24
NOXAFIL	Delayed-release Tablets	posaconazole	100 mg	205053	1	2014-06-16
NOXAFIL	Oral Suspension	posaconazole	40 mg/mL	022003	1	2011-02-28

US Patents and Regulatory Information for POSACONAZOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014		DISCN	Yes	No			Y
Aet Pharma	POSACONAZOLE	posaconazole	TABLET, DELAYED RELEASE;ORAL	213454-001	Feb 1, 2021	AB	RX	No	Yes
Fresenius Kabi Usa	POSACONAZOLE	posaconazole	SOLUTION;INTRAVENOUS	209983-001	Dec 26, 2023	AP	RX	No	No
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014		DISCN	Yes	No
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014		DISCN	Yes	No			Y
Ph Health	POSACONAZOLE	posaconazole	SOLUTION;INTRAVENOUS	208768-001	May 25, 2022	AP	RX	No	No
Sinotherapeutics Inc	POSACONAZOLE	posaconazole	TABLET, DELAYED RELEASE;ORAL	212411-001	Aug 21, 2019	AB	RX	No	No

Expired US Patents for POSACONAZOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006
Schering	NOXAFIL	posaconazole	SUSPENSION;ORAL	022003-001	Sep 15, 2006
Merck Sharp Dohme	NOXAFIL	posaconazole	TABLET, DELAYED RELEASE;ORAL	205053-001	Nov 25, 2013
Merck Sharp Dohme	NOXAFIL	posaconazole	TABLET, DELAYED RELEASE;ORAL	205053-001	Nov 25, 2013
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014

EU/EMA Drug Approvals for POSACONAZOLE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp and Dohme B.V	Noxafil	posaconazole	EMEA/H/C/000610Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.	Authorised	no	no	no	2005-10-25
Accord Healthcare S.L.U.	Posaconazole AHCL	posaconazole	EMEA/H/C/005028Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	Authorised	yes	no	no	2019-07-25
Accord Healthcare S.L.U.	Posaconazole Accord	posaconazole	EMEA/H/C/005005Posaconazole Accord is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole Accord is also indicated for prophylaxis of invasive fungal infections in the following patients: Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	Authorised	yes	no	no	2019-07-25
Schering-Plough Europe	Posaconazole SP	posaconazole	EMEA/H/C/000611Posaconazole SP is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole SP is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who areat high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.	Withdrawn	no	no	no	2005-10-25

International Patents for POSACONAZOLE

Country	Patent Number	Title	Estimated Expiration
Australia	2009241858
Brazil	PI0905080
Canada	2702603
Canada	2771879
China	101959508
China	105288650
China	114053423

Supplementary Protection Certificates for POSACONAZOLE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0736030	SPC/GB06/007	United Kingdom		PRODUCT NAME: POSACONAZOLE, OPTIONALLY IN THE FORM OF AN ESTER OR PHARMACEUTICALLY ACCEPTABLE SALT.; REGISTERED: UK EU/1/05/320/001 20051025; UK EU/1/05/321/001 20051025
0736030	06C0009	France		PRODUCT NAME: POSACONAZOLE; REGISTRATION NO/DATE: EU/1/05/320/001 20051025

Posaconazole Market Dynamics and Financial Trajectory (U.S. and Key Global Drivers)

Last updated: June 20, 2026

Posaconazole is an antifungal with revenue driven by (1) intensive-care and hematology-oncology uptake of prophylaxis, (2) hospital formulary dynamics for intravenous and delayed-release oral products, and (3) uptake of branded and authorized generics and competing azoles. Financial trajectory is shaped by patent-and-exclusivity timing, rising price pressure, and formulary shifts toward lower-cost alternatives as exclusivity expires and generic penetration increases.

How does posaconazole make money in the market?

Revenue is concentrated in institutional channels (hospital pharmacy and group purchasing organizations) with procurement patterns governed by formulary tiering, IV availability, and payer coverage. Posaconazole is typically positioned for:

• Breakthrough and invasive fungal infection treatment (where guideline-aligned)
• Antifungal prophylaxis in high-risk hematology oncology and transplant settings
• Empiric therapy in febrile neutropenia when indicated by guidelines

What product forms drive posaconazole sales?

Market spend tracks the highest-value mix first:

• Delayed-release oral suspension (legacy branded exposure; historically associated with variable absorption)
• Oral delayed-release tablet (improved exposure consistency; drives formulary preference in many systems)
• Intravenous (IV) infusion (used when oral dosing is not feasible)

What are the dominant buyer segments?

• Tertiary hospitals and academic medical centers
• Oncology centers running hematopoietic stem cell transplantation (HSCT) programs
• Long-stay inpatient oncology wards with high prophylaxis protocols

What market dynamics affect posaconazole pricing and volume?

Pricing is pressured by generic erosion and by payer scrutiny of high-cost antifungals. Volume is pressured by stewardship and by protocol migration toward agents with similar spectrum, faster administration, or lower acquisition cost.

How do hospital formularies influence posaconazole uptake?

Hospital formularies typically shift in stepwise fashion:

• Year-1: branded or authorized generic retention for continuity
• Year-2 onward: tender-based switching when multiple lower-cost options are available
• IV-to-oral migration: when oral tablet protocols meet clinical targets and allow step-down

What competitors shape adoption?

Posaconazole competes within broad azole and antifungal classes, with clinical positioning depending on indication:

• Voriconazole and isavuconazole (systemic azole comparators)
• Amphotericin B formulations (guideline-relevant comparator in some protocols)
• Newer or competing antifungals and stewardship-driven selection in hospital pathways

When does posaconazole face generic entry risk from patent expiration and exclusivity?

Generic entry risk depends on the patent estate around the specific posaconazole product form and on regulatory exclusivity tied to the branded NDA. The market effect is usually “front-loaded” around ANDA approvals and “back-loaded” around actual hospital procurement changes.

What exclusivity and patent mechanisms govern U.S. generic timelines?

• Orange Book-listed patent expirations for the relevant NDA
• Method-of-use patents (if any cover prophylaxis indications)
• Formulation patents for delayed-release technologies and specific dosage forms
• Exclusivity tied to NDA approvals and supplements (where applicable)

How does Paragraph IV litigation affect market timing?

Where a Paragraph IV challenge is filed, settlement can delay generic launch while still accelerating volume shifts to alternative agents ahead of generic availability, depending on formulary flexibility.

What is the typical market pattern after first generic launches?

• Initial: limited volume capture as clinicians and pharmacists test substitution policy
• Middle: larger share as GPO pricing and contracting changes
• Late: conversion to lowest net cost, including authorized generics or multiple generics

What is the Orange Book status of posaconazole products?

Orange Book status is determined by the specific branded NDA and product (tablet, suspension, or IV formulation). Patent coverage can differ by product form, which changes the near-term risk profile for generics and the defensibility for branded incumbents.

Which posaconazole NDA/product codes matter for exclusivity?

The market impact hinges on Orange Book listings tied to:

• The exact NDA for posaconazole delayed-release oral tablet
• The exact NDA for posaconazole IV and/or delayed-release suspension
• Any NDA supplements for line extensions (such as new formulations or manufacturing changes)

How many patents cover posaconazole and what categories do they fall into?

Patent estates typically cluster into:

• Composition of matter around the drug substance (if still relevant)
• Formulation patents for delayed-release and absorption control
• Manufacturing process patents
• Method-of-use patents for prophylaxis or treatment protocols (if listed)

How strong is the patent estate for posaconazole vs likely generic attack points?

The practical strength metric is whether meaningful claims cover:

• The commercial dosage form used in hospitals
• The marketed clinical indication via method-of-use claims
• The manufacturing process that ANDAs must replicate to meet specs

What generic entry risks exist for posaconazole delayed-release tablets vs suspension?

Generic risk differs by:

• Formulation complexity (delayed-release controls can be harder to match)
• Bioequivalence requirements and dissolution behavior constraints
• Hospital preference for more predictable exposure formulations (tablet vs suspension)

Why delayed-release tablets can remain harder to displace than suspension in some formularies

If hospitals standardized on delayed-release tablets due to perceived consistency, conversion pressure increases only when:

• Net price gaps widen enough to offset perceived clinical or workflow preferences
• Substitution policies explicitly permit interchange

What patent litigation affects posaconazole generic competition?

Litigation influences the timeline for ANDA approvals and launch. The market effect is measured by:

• Whether settlements allow early launches
• Whether court outcomes narrow claim coverage for formulation or method-of-use
• Whether multiple filers create “parallel generic pressure,” accelerating price erosion

How to read litigation outcomes for market impact

• Settlements tied to “entry on a specific date” usually compress the window for incumbent price maintenance
• Outcomes that preserve method-of-use claims can limit label-based switching in certain indications

What is the FDA regulatory trajectory for posaconazole, including approval and pathway signals?

FDA trajectory is shaped by:

• Original NDA approvals and subsequent supplements
• Regulatory approvals for generics and authorized generics
• Any label updates reflecting new indications or safety communications

Does posaconazole face REMS or major label restrictions that impact volume?

Material volume impact typically arises from:

• Safety communications that alter prescribing behavior
• Label restrictions that narrow use in specific patient groups
• Monitoring requirements that change provider and hospital workflow

How do contracts, tendering, and GPO pricing change posaconazole revenue?

Institutional contracting is the dominant lever for branded revenue stability and generic substitution speed.

What drives net price vs list price for posaconazole?

• Rebates tied to volume commitments
• GPO-negotiated pricing
• Contract-specific exclusions or switching rules
• Inventory management and formulary tier penalties

What happens when multiple generics launch?

When at least two ANDAs are broadly launched into major channels:

• Competitive price floors drop
• Short-term inventory hoarding by hospitals can create temporary supply shocks
• Net price erodes faster than acquisition volume grows

How does posaconazole compare with competing antifungals on market economics?

Comparison is best framed on total cost-of-therapy and procurement convenience:

• Oral vs IV pathway needs
• Administration time and inpatient workflow
• Expected monitoring and safety management burden

How do acquisition costs and stewardship shift choices?

Stewardship programs reduce unnecessary antifungal exposure. If competing agents cover similar indications at lower net cost and with similar tolerability, posaconazole volume can soften even if clinical demand remains steady.

What product lifecycle events shape posaconazole financial trajectory?

Key lifecycle drivers include:

• Loss of exclusivity for specific dosage forms
• Introduction of authorized generics or full generics
• Protocol standardization that can either preserve or reduce usage
• Patent expiry that changes the speed of generic conversion

What is the most common “earnings inflection” pattern?

• Pre-expiry: branded revenue supported by formulary loyalty and rebate structure
• Post-expiry: rapid net price decline and shrinking gross margin
• Mid-term: stabilization as the market consolidates around cheapest contracted options

Where is posaconazole revenue concentrated geographically?

Sales concentration depends on:

• HSCT and oncology density
• Reimbursement structures
• Generic penetration rates in each market
• Regulatory and procurement norms for hospital antifungals

How does generic uptake differ by region?

• U.S.: large institutional penetration with faster ANDA-driven erosion after launches
• EU and UK: tender-driven competition with varying time lags based on local approvals and interchangeability norms
• Emerging markets: slower uptake in some settings where pharmacy procurement is less centralized

What are the revenue exposure and downside scenarios for the incumbent?

Revenue downside depends on:

• Speed of generic conversion in tablets or IV first
• Whether the incumbent maintains formulary status through contracting and clinical positioning
• Whether new entrants flood tender markets simultaneously

Scenario framework (market mechanics)

• Base: gradual erosion as contracts cycle and substitution expands
• Downside: sharp erosion when multiple generics are simultaneously contracted at scale
• Upside: slower erosion if the incumbent retains higher tiers via evidence-backed clinical or workflow advantages and locks rebate/contract terms

Key Takeaways

• Posaconazole revenue is driven by institutional prophylaxis and treatment workflows, with mix influenced by tablet vs IV vs suspension availability.
• Market dynamics hinge on formulary tiering, GPO contracting, and stewardship protocols that determine switching behavior.
• Financial trajectory is primarily shaped by loss of exclusivity and patent estate pressure specific to each dosage form, followed by generic and authorized-generic penetration.
• Litigation and settlement outcomes can delay generic entry and compress branded price maintenance windows.
• Earnings inflections usually track ANDA launch timing and contract cycles, with net price erosion often faster than volume changes.

FAQs

1. Does posaconazole delayed-release tablet have different generic entry timing than IV or suspension?
2. How do method-of-use patents for antifungal prophylaxis affect generic substitution and label switching?
3. What tends to happen to hospital formulary position for posaconazole after first ANDA approvals?
4. Which posaconazole patient populations most strongly influence quarterly volume volatility?
5. How do rebate and GPO contracts typically change net pricing for high-cost antifungals like posaconazole?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (accessed 2026-06-21).
2. FDA. Drug Approval Package: posaconazole (NDA-specific pages). U.S. Food and Drug Administration. (accessed 2026-06-21).
3. FDA. Drugs@FDA: posaconazole. U.S. Food and Drug Administration. (accessed 2026-06-21).